The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.
Kazuomi Ueshima
Honoraria - Bayer; Chugai Pharma; EA Pharma; Eisai; Kowa; Lilly Japan; MSD; Sumitomo Group; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda; Takeda
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Takeharu Yamanaka
Honoraria - Bayer; Chugai Pharma; Takeda
Research Funding - Bayer (Inst); Chugai/Roche (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Hiroshi Aikata
Honoraria - Eisai
Tatsuya Yamashita
Speakers' Bureau - Chugai Pharma; Eisai; Lilly
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
Ryosuke Tateishi
Honoraria - Abbvie; Bayer Yakuhin; Daiichi Sankyo; Eisai; Fujifilm; GE Healthcare; Gilead Sciences; Merck Sharp & Dohme; Otsuka; Shionogi; Sumitomo Dainippon; Taisho Toyama Pharma
Consulting or Advisory Role - Bayer Yakuhin; Shionogi
Michihisa Moriguchi
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly Japan
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly Japan
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); MSD K.K (Inst)
Atsushi Hiraoka
Speakers' Bureau - Bayer; Eisai
Kaoru Tsuchiya
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Lilly
Sadahisa Ogasawara
Honoraria - Bayer; Eisai; Lilly; Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly; Merck
Research Funding - Bayer; Eisai; Lilly
Satoshi Mochida
Honoraria - Abbvie; ASKA Pharmaceutical; Gilead Sciences; MSD K.K; Otsuka; Sumitomo Group
Research Funding - Abbvie; ASKA Pharmaceutical; Chugai Pharma; CMIC; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; Janssen; Kowa; Mic medical; Mochida Pharmaceutical Co. Ltd.; Sumitomo Group; Toray Industries
Shiro Miyayama
No Relationships to Disclose
Kiyoshi Hasegawa
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; Taiho Pharmaceutical; Takeda
Research Funding - Fujifilm (Inst); Nipro Corporation (Inst); Shimadzu (Inst)
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihonkayaku; Novartis; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku
Tetsuo Takehara
No Relationships to Disclose